Discover

News & Info

Trade

LongbridgeAI

Quote List Quote List

RIBOLIFE-B(06938.HK)

Event Tracking

Apr14

RiboBio-B Submits Clinical Trial Application for Vortosiran to EMA

00:06

Apr1

Citi Analyst Maintains Buy Rating on Suzhou Ribo Biotech H Shares with Target Price of HKD 102.00

01:13

Mar25

RIBOLIFE-B released FY2025 9 Months earnings on March 25 (BJT), actual revenue HKD 136.83 M, actual EPS HKD -1.5112

15:00

RIBOLIFE-B released FY2025 Q3 earnings on March 25, 2026 (BJT) with actual revenue of HKD 24.43 M and EPS of HKD -0.7757

15:00

RiboBio-B Reports 2025 Earnings, Increased R&D Spend, and New Licensing Agreement with Madrigal

14:41

RIBOLIFE-B released FY2025 Q4 earnings on March 25 After-Market (BJT), actual revenue HKD 24.85 M, actual EPS HKD -0.789

11:00

Schedules & Filings

Schedules

Filings

Mar25

Earning Release(CST)

FY2025 Q4 Earning Release (HKD) Revenue 24.85 M, Net Income -105.61 M, EPS -0.789

Jan9

IPO(CST)

Listing Price HKD 57.97

Dec30

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 56.81 M, Net Income -48.22 M, EPS -0.371

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

RIBOLIFE-B(06938.HK)

RIBOLIFE-B Stock Performance Chart